
  
    
      
        Background_NNP
        Ribozymes_NNP whose_WP$ activities_NNS are_VBP modulated_JJ by_IN effector_NN
        molecules_NNS have_VBP previously_RB been_VBN engineered_VBN ._. For_IN example_NN ,_,
        Herschlag_NNP and_CC co-workers_NNS have_VBP previously_RB shown_VBN that_IN a_DT
        nucleobase_NN could_MD complement_VB an_DT abasic_JJ site_NN within_IN the_DT
        hammerhead_NN ribozyme_NN ,_, restoring_VBG cleavage_NN activity_NN [_NN 1_CD ]_NN ._.
        Similarly_RB ,_, Porta_NNP and_CC Lizardi_NNP engineered_VBN a_DT hammerhead_NN
        ribozyme_NN that_WDT assumed_VBD an_DT inactive_JJ secondary_JJ structure_NN ;_: upon_IN
        the_DT addition_NN of_IN an_DT oligonucleotide_NN that_WDT disrupted_VBD the_DT
        engineered_VBN secondary_JJ structure_NN ,_, the_DT ribozyme_NN was_VBD activated_VBN
        [_NN 2_CD ]_NN ._. More_RBR recently_RB ,_, it_PRP has_VBZ previously_RB been_VBN shown_VBN that_IN
        many_JJ selected_VBN nucleic_JJ acid_NN binding_JJ species_NNS (_( aptamers_NNS )_)
        undergo_VBP conformational_NN changes_NNS upon_IN ligand_NN binding_JJ [_NN 3_CD 4_CD 5_CD
        6_CD ]_NN In_IN addition_NN ,_, when_WRB aptamers_NNS are_VBP conjoined_JJ to_TO ribozymes_NNS ,_,
        the_DT ligand-induced_JJ conformational_NN changes_NNS in_IN the_DT aptamers_NNS
        frequently_RB modulate_VBP the_DT structures_NNS and_CC hence_RB the_DT activities_NNS
        of_IN the_DT ribozymes_NNS [_NN 7_CD 8_CD 9_CD ]_NN For_IN example_NN ,_, binding_JJ of_IN
        theophylline_NN to_TO the_DT anti-theophylline_JJ aptamer_NN [_NN 10_CD ]_NN
        modulates_NNS the_DT conformation_NN of_IN residue_NN [_NN 11_CD 12_CD ]_NN and_CC the_DT
        overall_JJ stability_NN of_IN the_DT aptamer_NN [_NN 10_CD 13_CD ]_NN ._. Appending_NNP the_DT
        anti-theophylline_JJ aptamer_NN to_TO the_DT hammerhead_NN ribozyme_NN
        allowed_VBD cleavage_NN activity_NN to_TO be_VB modulated_JJ by_IN 110_CD -_: fold_VB by_IN
        theophylline_NN [_NN 13_CD ]_NN ._. Similarly_RB ,_, appending_VBG the_DT
        anti-theophylline_JJ aptamer_NN to_TO a_DT small_JJ ribozyme_NN ligase_NN (_( L_NNP 1_LS )_)
        generated_VBD an_DT aptazyme_NN that_WDT was_VBD activated_VBN 1_CD ,_, 600_CD -_: fold_VB by_IN
        saturating_VBG theophylline_NN concentrations_NNS [_NN 14_CD ]_NN ._.
        The_DT methods_NNS for_IN engineering_NN and_CC selecting_VBG Group_NNP I_PRP
        aptazymes_NNS appear_VBP to_TO be_VB generalizable_JJ to_TO several_JJ different_JJ
        types_NNS of_IN ribozymes_NNS ._. Adjoining_NNP aptamers_NNS to_TO the_DT Group_NNP I_PRP
        self-splicing_JJ intron_NN would_MD potentially_RB allow_VB the_DT control_NN of_IN
        splicing_VBG not_RB only_RB 
        in_IN vitro_NN ,_, but_CC 
        in_IN vivo_NN ._. To_TO this_DT end_NN ,_, we_PRP have_VBP
        attempted_VBN to_TO generate_VB and_CC assay_NN Group_NNP I_PRP aptazymes_NNS ._.
      
      
        Results_NNS and_CC Discussion_NNP
        
          Design_NNP of_IN Group_NNP I_PRP aptazymes_NNS
          In_IN order_NN to_TO convert_VB the_DT Group_NNP I_PRP self-splicing_JJ intron_NN
          to_TO a_DT regulatable_JJ aptazyme_NN ,_, it_PRP was_VBD necessary_JJ to_TO first_JJ
          identify_VB sequences_NNS or_CC structures_NNS in_IN the_DT ribozyme_NN whose_WP$
          conformation_NN might_MD modulate_VBP splicing_VBG activity_NN ._. The_DT
          structural_JJ and_CC kinetic_JJ properties_NNS of_IN the_DT Group_NNP I_PRP
          self-splicing_JJ intron_NN from_IN the_DT 
          thymidylate_NN synthase_NN (_( 
          td_NN )_) gene_NN in_IN bacteriophage_NN T_NN 4_CD have_VBP
          been_VBN extensively_RB studied_VBN ._. In_IN particular_JJ ,_, a_DT series_NN of_IN
          nested_JJ deletions_NNS of_IN the_DT P_NN 6_CD stem-loop_JJ have_VBP been_VBN shown_VBN to_TO
          partially_RB or_CC completely_RB compromise_VB ribozyme_NN activity_NN [_NN 15_CD
          ]_NN ._. More_RBR importantly_RB ,_, either_CC magnesium_NN or_CC the_DT tyrosyl_NN
          tRNA_NN synthetase_NN from_IN Neurospora_NNP mitochondria_NN (_( CYT_NNP 18_CD )_) can_MD
          suppress_VB many_JJ of_IN these_DT defects_NNS [_NN 16_CD 17_CD ]_NN ._. Previous_JJ
          studies_NNS with_IN other_JJ introns_NNS have_VBP also_RB revealed_VBN that_DT
          deletion_NN of_IN the_DT P_NN 5_CD stem-loop_JJ can_MD modulate_VBP ribozyme_NN
          activity_NN [_NN 18_CD 19_CD ]_NN ._. We_PRP hypothesized_VBN that_IN sites_NNS where_WRB
          deletions_NNS modulated_JJ ribozyme_NN activity_NN might_MD also_RB prove_VB to_TO
          be_VB sites_NNS where_WRB aptamer_NN conformational_NN changes_NNS would_MD
          modulate_VBP ribozyme_NN activity_NN ._. Based_VBN on_IN these_DT studies_NNS ,_, we_PRP
          designed_VBD a_DT series_NN of_IN Group_NNP I_PRP aptazymes_NNS in_IN which_WDT the_DT
          anti-theophylline_JJ aptamer_NN was_VBD substituted_VBN for_IN either_DT a_DT
          portion_NN of_IN P_NN 6_CD or_CC P_NN 5_CD (_( Figure_NN 1_LS )_) ._. The_DT anti-theophylline_JJ
          aptamer_NN was_VBD attached_VBN at_IN the_DT same_JJ point_NN as_IN had_VBN previously_RB
          proven_VBN successful_JJ in_IN the_DT design_NN of_IN theophylline-dependent_JJ
          cleavases_NNS and_CC ligases_NNS [_NN 13_CD 14_CD ]_NN ._.
        
        
          Activation_NNP in_IN vitro_NN
          The_DT self-splicing_JJ activities_NNS of_IN the_DT Group_NNP I_PRP aptazymes_NNS
          were_VBD examined_VBN 
          in_IN vitro_NN using_VBG a_DT standard_JJ splicing_VBG
          assay_NN (_( Table_NNP 1_LS )_) ._. Magnesium_NNP had_VBD previously_RB been_VBN shown_VBN to_TO
          suppress_VB structural_JJ defects_NNS in_IN the_DT 
          td_NN intron_NN ,_, and_CC ligand-induced_JJ
          suppressions_NNS of_IN splicing_VBG defects_NNS were_VBD examined_VBN by_IN
          carrying_VBG out_IN splicing_VBG reactions_NNS at_IN either_DT low_JJ (_( 3_CD mM_NN ,_,
          stringent_JJ )_) or_CC high_JJ (_( 8_CD mM_NN ,_, permissive_JJ )_) magnesium_NN
          concentrations_NNS [_NN 15_CD ]_NN ._. Several_JJ of_IN the_DT constructs_NNS were_VBD
          either_CC relatively_RB inactive_JJ (_( e_SYM ._. g_SYM ._. ,_, Th_NNP 3_CD P_NN 6_CD ,_, Th_NNP 5_CD P_NN 6_CD ,_, and_CC
          Th_NNP 6_CD P_NN 6_CD )_) or_CC did_VBD not_RB consistently_RB show_VB differential_NN splicing_VBG
          activity_NN (_( e_SYM ._. g_SYM ._. ,_, Th_NNP 4_CD P_NN 6_CD and_CC Th_NNP 2_CD P_NN 5_LS )_) ._. However_RB ,_, four_CD of_IN the_DT
          constructs_NNS ,_, Th_NNP 1_CD P_NN 6_CD ,_, Th_NNP 2_CD P_NN 6_CD ,_, Th_NNP 3_CD P_NN 6_CD ,_, and_CC Th_NNP 1_CD P_NN 5_CD ,_, showed_VBD good_JJ
          activity_NN (_( >_NN 10_CD %_NN of_IN wild-type_JJ )_) and_CC increased_VBN
          self-splicing_JJ in_IN the_DT presence_NN of_IN theophylline_NN ._. For_IN
          example_NN ,_, Th_NNP 2_CD P_NN 6_CD showed_VBD the_DT greatest_JJS activation_NN (_( 8_CD -_: fold_VB at_IN
          8_CD mM_NN MgCl_NNP 
          2_LS )_) ,_, while_IN Th_NNP 1_CD P_NN 5_CD showed_VBD low_JJ activation_NN
          (_( 1_CD ._. 2_LS -_: fold_VB )_) at_IN both_DT magnesium_NN concentrations_NNS ._.
          For_IN all_DT of_IN the_DT aptazymes_NNS except_IN Th_NNP 3_CD P_NN 6_CD ,_, the_DT
          ligand-induced_JJ splicing_VBG activity_NN was_VBD greater_JJR in_IN a_DT
          standard_JJ assay_NN at_IN the_DT more_RBR stringent_JJ (_( 3_CD mM_NN )_) magnesium_NN
          concentration_NN (_( Table_NNP 1_LS )_) ._. The_DT construct_VB Th_NNP 3_CD P_NN 6_CD was_VBD inactive_JJ
          at_IN lower_JJR magnesium_NN concentrations_NNS ,_, but_CC underwent_VBD
          ligand-induced_JJ splicing_VBG at_IN the_DT more_RBR permissive_JJ
          concentration_NN (_( 8_CD mM_NN )_) ._. Interestingly_RB ,_, those_DT aptazyme_NN
          constructs_NNS that_WDT showed_VBD ligand-dependent_JJ activity_NN closely_RB
          resembled_JJ the_DT original_JJ deletion_NN variants_NNS that_WDT showed_VBD
          magnesium-dependent_JJ recovery_NN of_IN splicing_VBG activity_NN ._. For_IN
          example_NN ,_, the_DT junction_NN between_IN the_DT aptamer_NN and_CC the_DT Group_NNP I_PRP
          ribozyme_NN in_IN the_DT aptazyme_NN Th_NNP 2_CD P_NN 6_CD resembled_JJ the_DT deletion_NN
          variant_NN 
          td_NN Î”P_NN 6_CD -_: 6_CD ;_: the_DT aptazyme_NN was_VBD
          activated_VBN by_IN theophylline_NN ,_, while_IN the_DT splicing_VBG defect_NN of_IN
          the_DT deletion_NN variant_NN at_IN 3_CD mM_NN magnesium_NN was_VBD suppressed_VBN by_IN
          8_CD mM_NN magnesium_NN or_CC by_IN stabilization_NN of_IN a_DT tetraloop_NN
          sequence_NN that_WDT capped_VBD the_DT P_NN 6_CD helix_NN [_NN 15_CD ]_NN ._. Defects_NNP that_DT
          poise_NN a_DT ribozyme_NN between_IN active_JJ and_CC inactive_JJ conformers_NNS
          have_VBP previously_RB been_VBN used_VBN to_TO engineer_VB effector-dependence_JJ
          [_NN 20_CD ]_NN ._.
          The_DT kinetics_NNS of_IN splicing_VBG of_IN two_CD of_IN the_DT most_RBS activated_VBN
          variants_NNS ,_, Th_NNP 1_CD P_NN 5_CD and_CC Th_NNP 2_CD P_NN 6_CD ,_, were_VBD examined_VBN in_IN the_DT presence_NN
          and_CC absence_NN of_IN theophylline_NN (_( Figure_NN 2_LS )_) ._. As_IN in_IN the_DT single_JJ
          point_NN assays_NNS ,_, the_DT theophylline-dependence_JJ of_IN the_DT
          engineered_VBN introns_NNS was_VBD readily_RB apparent_JJ (_( Figure_NN 2_CD a_DT )_) ._. The_DT
          time_NN courses_NNS reveal_VBP that_IN the_DT extents_NNS of_IN splicing_VBG of_IN the_DT
          aptazymes_NNS were_VBD significantly_RB affected_VBN by_IN the_DT addition_NN of_IN
          theophylline_NN (_( Figures_NNS 2_CD b_SYM ,_, 2_CD c_SYM )_) ._. The_DT aptazyme_NN modified_VBN at_IN P_NN 5_CD
          (_( Th_NNP 1_CD P_NN 5_LS )_) showed_VBD less_RBR theophylline-dependent_JJ enhancement_NN of_IN
          the_DT extent_NN of_IN reaction_NN than_IN the_DT aptazyme_NN modified_VBN at_IN P_NN 6_CD
          (_( Th_NNP 2_CD P_NN 6_CD )_) ,_, consistent_JJ with_IN the_DT single_JJ point_NN assays_NNS
          described_VBD above_IN ._. Th_NNP 1_CD P_NN 5_CD was_VBD activated_VBN 1_CD ._. 4_CD -_: fold_VB at_IN 15_CD
          minutes_NNS (_( Figure_NN 2_CD b_SYM )_) ,_, while_IN Th_NNP 2_CD P_NN 6_CD showed_VBD a_DT 4_CD ._. 0_CD -_: fold_VB rate_NN
          enhancement_NN at_IN 15_CD minutes_NNS (_( Figure_NN 2_CD c_SYM )_) ._. These_DT levels_NNS of_IN
          ligand-dependent_JJ activation_NN were_VBD similar_JJ to_TO those_DT
          observed_VBD with_IN the_DT original_JJ hammerhead_NN aptazyme_NN
          constructs_NNS ,_, [_NN 21_CD ]_NN and_CC it_PRP may_MD prove_VB possible_JJ to_TO use_VB 
          in_IN vitro_NN selection_NN to_TO further_VB
          optimize_NN activation_NN [_NN 13_CD 14_CD ]_NN ._. However_RB ,_, when_WRB the_DT time_NN
          course_NN data_NNS were_VBD fit_VBN with_IN a_DT single_JJ exponential_NN equation_NN ,_,
          the_DT rates_NNS of_IN the_DT initial_JJ reactions_NNS turned_VBD out_IN to_TO be_VB very_RB
          similar_JJ in_IN both_DT the_DT presence_NN and_CC absence_NN of_IN theophylline_NN
          (_( Table_NNP 2_LS )_) ._.
          Based_VBN on_IN these_DT results_NNS ,_, the_DT primary_JJ mechanism_NN of_IN
          activation_NN is_VBZ likely_JJ the_DT same_JJ as_IN has_VBZ been_VBN observed_VBN for_IN
          other_JJ aptazymes_NNS :_: ligand-induced_JJ conformational_NN changes_NNS
          that_WDT stabilize_VBP functional_JJ ribozyme_NN sequences_NNS and_CC
          structures_NNS ._. However_RB ,_, the_DT Group_NNP I_PRP self-splicing_JJ intron_NN is_VBZ
          a_DT much_RB more_RBR complicated_JJ ribozyme_NN than_IN either_DT the_DT
          hammerhead_NN or_CC the_DT L_NNP 1_CD ligase_NN ;_: for_IN example_NN ,_, the_DT tertiary_JJ
          structure_NN of_IN the_DT Group_NNP I_PRP intron_NN is_VBZ established_VBN by_IN a_DT
          complicated_VBN folding_VBG pathway_NN ._. [_NN 22_CD 23_CD 24_CD 25_CD 26_CD ]_NN
          Therefore_RB ,_, it_PRP was_VBD possible_JJ that_IN theophylline-binding_JJ
          influenced_VBD the_DT overall_JJ folding_NN pathway_NN of_IN the_DT engineered_VBN
          Group_NNP I_PRP aptazyme_NN ._. In_IN order_NN to_TO assess_VB this_DT possibility_NN we_PRP
          examined_VBD the_DT theophylline-dependence_JJ of_IN Th_NNP 2_CD P_NN 6_CD splicing_VBG
          reactions_NNS 
          in_IN vitro_NN following_VBG prolonged_JJ
          incubation_NN (_( 30_CD minutes_NNS )_) to_TO allow_VB for_IN re-folding_JJ ._. No_DT
          significant_JJ change_NN in_IN the_DT extent_NN of_IN ligand-dependent_JJ
          activation_NN was_VBD observed_VBN following_VBG pre-incubation_JJ (_( data_NNS
          not_RB shown_VBN )_) ._. These_DT results_NNS argue_VBP that_IN both_DT GTP_NNP and_CC
          theophylline_NN may_MD need_VB to_TO be_VB present_JJ to_TO influence_VB the_DT
          folding_VBG pathway_NN of_IN the_DT engineered_VBN Group_NNP I_PRP aptazymes_NNS ._.
          These_DT results_NNS are_VBP also_RB consistent_JJ with_IN previous_JJ physical_JJ
          [_NN 27_CD ]_NN and_CC kinetic_JJ [_NN 28_CD 29_CD 30_CD ]_NN data_NNS that_WDT shows_VBZ that_IN the_DT
          folding_NN of_IN the_DT Group_NNP I_PRP intron_NN is_VBZ dependent_JJ in_IN part_NN upon_IN
          GTP_NNP ._.
        
        
          Gene_NNP regulation_NN in_IN vivo_NN
          Each_DT of_IN the_DT successful_JJ aptazyme_NN constructs_NNS was_VBD
          subsequently_RB cloned_VBN into_IN an_DT interrupted_VBN 
          thymidylate_NN synthase_NN gene_NN in_IN place_NN
          of_IN the_DT parental_JJ 
          td_NN self-splicing_JJ intron_NN ._. The_DT
          vectors_NNS were_VBD introduced_VBN into_IN an_DT 
          E_NNP ._. coli_NNS strain_VBP (_( C_NNP 600_CD ThyA_NNP :_: :_: Kan_NNP R_NNP )_)
          that_WDT lacked_VBD a_DT functional_JJ 
          thymidylate_NN synthase_NN gene_NN and_CC that_DT
          was_VBD a_DT thymidine_NN auxotroph_NN ._. When_WRB bacteria_NNS grown_VBN in_IN rich_JJ
          media_NNS were_VBD subsequently_RB plated_JJ on_IN minimal_JJ media_NNS lacking_VBG
          thymidine_NN ,_, no_DT colony_NN growth_NN was_VBD observed_VBN with_IN the_DT
          exception_NN of_IN Th_NNP 1_CD P_NN 5_CD ._. However_RB ,_, when_WRB theophylline_NN (_( 7_CD ._. 5_LS mM_NN )_)
          was_VBD included_VBN in_IN the_DT minimal_JJ media_NNS ,_, bacteria_NNS containing_VBG
          the_DT intron_NN Th_NNP 2_CD P_NN 6_CD formed_VBN colonies_NNS ,_, and_CC bacteria_NNS containing_VBG
          the_DT intron_NN Th_NNP 1_CD P_NN 5_CD showed_VBD increased_VBN growth_NN (_( Figure_NN 3_LS )_) ._. All_DT
          introns_NNS that_WDT originally_RB showed_VBD no_DT or_CC low_NN splicing_VBG 
          in_IN vitro_NN (_( including_VBG Th_NNP 3_CD P_NN 6_CD )_) could_MD
          not_RB rescue_VB bacteria_NNS either_CC in_IN the_DT presence_NN or_CC absence_NN of_IN
          theophylline_NN ._. Finally_RB ,_, no_DT growth_NN was_VBD observed_VBN in_IN a_DT
          negative_JJ control_NN that_WDT contained_VBD a_DT non-functional_JJ Group_NNP I_PRP
          intron_NN (_( B_NNP 11_CD )_) ,_, and_CC no_DT theophylline-dependent_JJ changes_NNS in_IN
          growth_NN were_VBD observed_VBN in_IN a_DT negative_JJ control_NN in_IN which_WDT
          mutations_NNS were_VBD introduced_VBN into_IN the_DT aptazyme_NN to_TO abolish_VB
          theophylline_NN binding_JJ (_( Th_NNP 2_CD P_NN 6_CD ._. D_NNP )_) ._. Interestingly_RB ,_, no_DT growth_NN
          was_VBD observed_VBN for_IN bacteria_NNS harboring_VBG the_DT intron_NN Th_NNP 1_CD P_NN 6_CD ,_,
          despite_IN the_DT fact_NN that_IN this_DT aptazyme_NN showed_VBD the_DT greatest_JJS
          activation_NN by_IN theophylline_NN 
          in_IN vitro_NN ._. The_DT plating_VBG results_NNS were_VBD
          consistent_JJ and_CC reproducible_JJ over_IN a_DT variety_NN of_IN
          experiments_NNS ._.
          To_TO better_JJR characterize_VB the_DT influence_NN of_IN the_DT effector_NN
          on_IN intron-splicing_JJ ,_, we_PRP also_RB carried_VBD out_RP a_DT series_NN of_IN
          growth_NN experiments_NNS in_IN liquid_JJ culture_NN (_( Figure_NN 4_CD a_DT )_) ._. An_DT
          overnight_JJ bacterial_JJ culture_NN that_WDT contained_VBD the_DT 
          td_NN gene_NN divided_VBN by_IN the_DT aptazyme_NN
          Th_NNP 2_CD P_NN 6_CD was_VBD inoculated_JJ into_IN fresh_JJ ,_, minimal_JJ media_NNS ,_, effector_NN
          was_VBD added_VBN ,_, and_CC growth_NN was_VBD continuously_RB monitored_VBN ._. As_IN
          expected_VBN based_VBN on_IN growth_NN assays_NNS on_IN solid_JJ media_NNS ,_, little_JJ
          growth_NN was_VBD observed_VBN in_IN the_DT absence_NN of_IN theophylline_NN ._.
          However_RB ,_, when_WRB theophylline_NN (_( 0_CD ._. 5_LS mM_NN )_) was_VBD added_VBN to_TO liquid_JJ
          medium_NN ,_, bacteria_NNS grew_VBD almost_RB as_RB well_RB as_IN a_DT control_NN in_IN
          which_WDT the_DT parental_JJ intron_NN was_VBD inserted_VBN into_IN the_DT 
          td_NN gene_NN ._. Most_JJS importantly_RB ,_,
          bacterial_JJ growth_NN was_VBD not_RB activated_VBN by_IN the_DT
          structurally-related_JJ effector_NN caffeine_NN (_( i_NNP ._. e_SYM ._. ,_,
          7_CD -_: methyltheophylline_NN )_) ;_: the_DT anti-theophylline_JJ aptamer_NN is_VBZ
          known_VBN to_TO discriminate_JJ between_IN caffeine_NN and_CC theophylline_NN
          by_IN a_DT factor_NN of_IN 10_CD ,_, 000_CD -_: fold_VB [_NN 10_CD ]_NN ._. No_DT effector-dependent_JJ
          growth_NN differences_NNS were_VBD observed_VBN with_IN cultures_NNS containing_VBG
          
          td_NN genes_NNS divided_VBN by_IN the_DT
          non-functional_JJ Group_NNP I_PRP intron_NN B_NNP 11_CD ._. Similar_JJ results_NNS were_VBD
          obtained_VBN with_IN cultures_NNS that_WDT contained_VBD the_DT 
          td_NN gene_NN divided_VBN by_IN the_DT aptazyme_NN
          Th_NNP 1_CD P_NN 5_CD (_( Figure_NN 4_CD b_SYM )_) ._. However_RB ,_, in_IN this_DT instance_NN there_EX was_VBD
          some_DT background_NN growth_NN of_IN uninduced_JJ bacteria_NNS ,_, consistent_JJ
          with_IN the_DT higher_JJR level_NN of_IN background_NN splicing_VBG activity_NN 
          in_IN vitro_NN ._. If_IN theophylline_NN is_VBZ
          regulating_VBG intron_NN splicing_VBG 
          in_IN vivo_NN ,_, then_RB the_DT extent_NN of_IN
          bacterial_JJ growth_NN should_MD be_VB dependent_JJ upon_IN the_DT
          concentration_NN of_IN theophylline_NN introduced_VBN into_IN the_DT media_NNS
          (_( Figure_NN 4_CD c_SYM )_) ._. However_RB ,_, theophylline_NN was_VBD toxic_JJ to_TO bacteria_NNS ,_,
          and_CC caused_VBD a_DT decrease_NN in_IN the_DT growth_NN of_IN bacteria_NNS
          containing_VBG the_DT parental_JJ 
          td_NN intron_NN at_IN concentrations_NNS greater_JJR
          than_IN 0_CD ._. 5_CD mM_NN ._. Consistent_NNP with_IN this_DT observation_NN ,_, low_JJ
          concentrations_NNS of_IN theophylline_NN progressively_RB increased_VBD
          bacterial_JJ growth_NN (_( by_IN activating_VBG the_DT 
          td_NN intron_NN )_) while_IN concentrations_NNS of_IN
          theophylline_NN above_IN 2_CD mM_NN progressively_RB decreased_VBD bacterial_JJ
          growth_NN (_( although_IN levels_NNS of_IN growth_NN were_VBD still_RB well_RB above_IN
          background_NN )_) ._.
          These_DT results_NNS were_VBD all_DT consistent_JJ with_IN the_DT hypothesis_NNS
          that_WDT theophylline_NN regulates_VBZ intron_NN splicing_VBG 
          in_IN vivo_NN ._. To_TO further_VB probe_NN whether_IN
          this_DT was_VBD in_IN fact_NN the_DT case_NN mRNA_NN was_VBD isolated_VBN from_IN 
          E_NNP ._. coli_NNS treated_VBN with_IN theophylline_NN
          or_CC not_RB ,_, and_CC RT-PCR_NNP was_VBD used_VBN to_TO confirm_VB the_DT presence_NN of_IN
          spliced_JJ introns_NNS (_( Figure_NN 5_LS )_) ._. For_IN each_DT of_IN the_DT introns_NNS known_VBN
          to_TO be_VB responsive_JJ to_TO theophylline_NN 
          in_IN vivo_NN (_( Th_NNP 2_CD P_NN 6_CD and_CC Th_NNP 1_CD P_NN 5_LS )_) an_DT
          increase_NN in_IN spliced_JJ mRNA_NN was_VBD observed_VBN ,_, while_IN most_JJS other_JJ
          introns_NNS that_WDT were_VBD not_RB responsive_JJ to_TO theophylline_NN 
          in_IN vivo_NN did_VBD not_RB show_VB an_DT increase_NN in_IN
          the_DT levels_NNS of_IN spliced_JJ mRNA_NN ._. An_DT exception_NN to_TO this_DT was_VBD
          Th_NNP 1_CD P_NN 6_CD ,_, which_WDT originally_RB showed_VBD theophylline-dependent_JJ
          splicing_VBG 
          in_IN vitro_NN and_CC also_RB showed_VBD
          theophylline-dependent_JJ splicing_VBG 
          in_IN vivo_NN ._. However_RB ,_, Th_NNP 1_CD P_NN 6_CD did_VBD not_RB
          mediate_VB theophylline-dependent_JJ growth_NN ._. The_DT bacterial_JJ
          mRNAs_NNS were_VBD extracted_VBN ,_, cloned_VBN ,_, and_CC sequenced_JJ ,_, and_CC half_NN of_IN
          them_PRP appeared_VBD to_TO use_VB a_DT cryptic_JJ splice_NN site_NN ._.
          Several_JJ discrepancies_NNS were_VBD noted_VBN between_IN intron_NN
          activation_NN 
          in_IN vitro_NN and_CC effector-dependent_JJ
          growth_NN ._. This_DT is_VBZ not_RB surprising_JJ ;_: other_JJ studies_NNS have_VBP
          revealed_VBN that_IN there_EX is_VBZ often_RB little_JJ correlation_NN between_IN
          ribozyme_NN activity_NN 
          in_IN vitro_NN and_CC 
          in_IN vivo_NN [_NN 31_CD ]_NN ._. However_RB ,_, since_IN it_PRP
          is_VBZ known_VBN that_IN relatively_RB small_JJ changes_NNS in_IN gene_NN expression_NN
          can_MD greatly_RB affect_VB the_DT metabolism_NN of_IN an_DT organism_NN ,_, another_DT
          possible_JJ explanation_NN for_IN the_DT apparent_JJ discrepancies_NNS is_VBZ
          that_IN relatively_RB small_JJ modulations_NNS in_IN intron_NN splicing_VBG are_VBP
          amplified_VBN via_IN cellular_JJ metabolism_NN to_TO yield_VB growth_NN
          phenotypes_NNS ._. This_DT would_MD seem_VB especially_RB true_JJ in_IN the_DT
          current_JJ set_NN of_IN experiments_NNS ,_, since_IN the_DT modulation_NN of_IN
          Thymidylate_NNP Synthase_NNP expression_NN is_VBZ known_VBN to_TO greatly_RB
          affect_VB thymidine_NN levels_NNS and_CC cell_NN growth_NN [_NN 32_CD ]_NN ._. For_IN
          example_NN ,_, 
          E_NNP ._. coli_NNS that_WDT are_VBP starved_VBN for_IN
          thymine_NN quickly_RB die_VB ,_, a_DT phenomenon_NN known_VBN as_IN '_POS thymineless_JJ
          death_NN '_'' [_NN 33_CD ]_NN ._. In_IN this_DT respect_NN ,_, Group_NNP I_PRP aptazymes_NNS that_WDT
          may_MD have_VB yielded_VBN lower_JJR amounts_NNS of_IN functional_JJ Thymidylate_NNP
          Synthase_NNP (_( e_SYM ._. g_SYM ._. ,_, Th_NNP 3_CD P_NN 6_CD ,_, which_WDT was_VBD less_RBR active_JJ than_IN Th_NNP 2_CD P_NN 6_CD ;_:
          or_CC Th_NNP 1_CD P_NN 6_CD ,_, which_WDT mis-spliced_JJ )_) did_VBD not_RB allow_VB bacterial_JJ
          growth_NN ._. In_IN contrast_NN ,_, aptazymes_NNS that_WDT may_MD have_VB yielded_VBN even_RB
          modestly_RB greater_JJR amounts_NNS of_IN functional_JJ Thymidylate_NNP
          Synthase_NNP (_( e_SYM ._. g_SYM ._. ,_, Th_NNP 1_CD P_NN 5_CD ,_, which_WDT was_VBD both_DT highly_RB active_JJ and_CC
          modestly_RB activated_VBN 
          in_IN vitro_NN )_) allowed_VBN bacterial_JJ
          growth_NN ._.
        
        
          Effector_NNP specificity_NN
          In_IN order_NN to_TO examine_VB effector-specificity_JJ 
          in_IN vivo_NN ,_, a_DT new_JJ series_NN of_IN Group_NNP I_PRP
          aptazymes_NNS was_VBD constructed_VBN in_IN which_WDT the_DT anti-theophylline_JJ
          aptamer_NN was_VBD mutated_VBN to_TO bind_NN 3_CD -_: methylxanthine_NN (_( 3_CD MeX_NNP 2_CD P_NN 6_CD )_) [_NN
          34_CD ]_NN ._. These_DT variants_NNS proved_VBD to_TO be_VB responsive_JJ to_TO
          3_CD -_: methylxanthine_NN both_DT 
          in_IN vitro_NN and_CC 
          in_IN vivo_NN (_( Figure_NN 6_CD a_DT )_) ._. However_RB ,_, the_DT
          variants_NNS were_VBD no_DT longer_RB responsive_JJ to_TO theophylline_NN ,_, nor_CC
          were_VBD they_PRP responsive_JJ to_TO a_DT variety_NN of_IN other_JJ analogues_NNS ,_,
          including_VBG caffeine_NN ,_, 1_CD -_: methylxanthine_NN ,_, 7_CD -_: methylxanthine_NN ,_,
          1_CD ,_, 3_CD -_: dimethyl_NN urilic_JJ acid_NN ,_, hypoxanthine_NN ,_, xanthine_NN ,_, and_CC
          theobromine_NN (_( Figure_NN 6_CD b_SYM )_) ._. In_IN contrast_NN ,_, the_DT original_JJ
          aptamer_NN was_VBD known_VBN to_TO also_RB bind_NN 3_CD -_: methylxanthine_NN ,_, and_CC the_DT
          original_JJ Group_NNP I_PRP aptazyme_NN (_( Th_NNP 2_CD P_NN 6_CD )_) also_RB proved_VBD to_TO be_VB
          responsive_JJ to_TO 3_CD -_: methylxanthine_NN 
          in_IN vivo_NN (_( Figure_NN 6_CD c_SYM )_) ._. Thus_RB ,_, the_DT
          responsivity_NN of_IN the_DT aptazymes_NNS 
          in_IN vivo_NN appears_VBZ to_TO mirror_VB their_PRP$
          effector_NN specificity_NN 
          in_IN vitro_NN ._.
        
        
          Applications_NNS
          The_DT ability_NN to_TO engineer_VB Group_NNP I_PRP introns_NNS to_TO be_VB
          responsive_JJ to_TO effector_NN molecules_NNS has_VBZ numerous_JJ potential_JJ
          applications_NNS ._. For_IN example_NN ,_, it_PRP may_MD prove_VB possible_JJ to_TO
          develop_VB new_JJ gene_NN therapies_NNS in_IN which_WDT patients_NNS rely_VBP upon_IN
          drugs_NNS that_WDT can_MD differentially_RB activate_VBP gene_NN expression_NN ,_,
          rather_RB than_IN having_VBG to_TO rely_VB upon_IN a_DT set_VBN level_NN of_IN endogenous_JJ
          expression_NN of_IN an_DT introduced_VBN gene_NN ._. Similarly_RB ,_, it_PRP may_MD prove_VB
          possible_JJ to_TO use_VB effector-dependent_JJ splicing_VBG to_TO more_RBR
          finely_RB monitor_VB gene_NN expression_NN 
          in_IN vivo_NN ._. A_DT drug_NN could_MD be_VB localized_VBN
          to_TO particular_JJ organs_NNS ,_, cells_NNS ,_, or_CC organelles_NNS ,_, and_CC splicing_VBG
          of_IN the_DT aptazyme_NN could_MD be_VB monitored_VBN via_IN a_DT reporter_NN gene_NN
          such_JJ as_IN luciferase_NN ._. It_PRP is_VBZ also_RB possible_JJ to_TO imagine_VB that_WDT
          engineered_VBN introns_NNS introduced_VBN into_IN reporter_NN genes_NNS may_MD
          find_VB application_NN in_IN high-throughput_JJ ,_, cell-based_JJ screening_NN
          assays_NNS that_WDT monitor_VBP drug_NN uptake_NN or_CC efficacy_NN ._. These_DT
          strategies_NNS should_MD prove_VB useful_JJ not_RB only_RB for_IN self-splicing_JJ
          introns_NNS activated_VBN by_IN drugs_NNS ,_, but_CC for_IN introns_NNS activated_VBN by_IN
          proteins_NNS or_CC peptides_NNS ._. In_IN this_DT regard_NN ,_, it_PRP is_VBZ notable_JJ that_IN
          some_DT natural_JJ Group_NNP I_PRP introns_NNS have_VBP proven_VBN to_TO be_VB highly_RB
          dependent_JJ upon_IN protein_NN cofactors_NNS ,_, [_NN 35_CD ]_NN and_CC that_IN Group_NNP I_PRP
          introns_NNS have_VBP been_VBN engineered_VBN whose_WP$ tertiary_JJ structure_NN and_CC
          activity_NN is_VBZ dependent_JJ upon_IN a_DT peptide_NN [_NN 36_CD ]_NN ._. Such_JJ
          applications_NNS could_MD also_RB be_VB melded_JJ with_IN other_JJ innovations_NNS
          dependent_JJ upon_IN the_DT Group_NNP I_PRP self-splicing_JJ intron_NN ,_, such_JJ as_IN
          the_DT introduction_NN of_IN a_DT trans-splicing_JJ intron_NN that_WDT can_MD
          potentially_RB repair_VB or_CC modulate_VBP the_DT expression_NN of_IN a_DT given_VBN
          mRNA_NN ._. [_NN 37_CD 38_CD 39_CD ]_NN
        
      
      
        Conclusions_NNP
        Group_NNP I_PRP aptazymes_NNS that_WDT were_VBD dependent_JJ upon_IN theophylline_NN
        both_DT 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN were_VBD engineered_VBN by_IN conjoining_VBG
        the_DT 
        thymidylate_NN synthase_NN (_( 
        td_NN )_) intron_NN with_IN an_DT anti-theophylline_JJ
        aptamer_NN ._. Although_IN the_DT 
        in_IN vitro_NN activation_NN of_IN splicing_VBG was_VBD
        modest_JJ (_( up_IN to_TO an_DT 18_CD -_: fold_VB change_NN in_IN initial_JJ rate_NN )_) ,_, this_DT
        change_NN was_VBD more_RBR than_IN enough_RB to_TO mediate_VB the_DT survival_NN of_IN a_DT
        thymidine-dependent_JJ 
        E_NNP ._. coli_NNS strain_VBP ._. The_DT ligand_NN
        specificity_NN of_IN the_DT anti-theophylline_JJ aptamer_NN carried_VBD over_IN
        to_TO the_DT theophylline-dependent_JJ aptazyme_NN ,_, and_CC no_DT activation_NN
        was_VBD seen_VBN with_IN caffeine_NN ,_, which_WDT differed_VBD by_IN a_DT single_JJ methyl_NN
        group_NN from_IN theophylline_NN ._. The_DT effector_NN specificity_NN could_MD be_VB
        rationally_RB changed_VBN by_IN changing_VBG the_DT specificity_NN of_IN the_DT
        conjoined_JJ aptamer_NN :_: when_WRB a_DT mutation_NN was_VBD introduced_VBN into_IN the_DT
        anti-theophylline_JJ aptamer_NN that_WDT led_VBD to_TO discrimination_NN
        against_IN theophylline_NN and_CC in_IN favor_NN of_IN 3_CD -_: methylxanthine_NN (_( that_IN
        also_RB differed_VBD from_IN theophylline_NN by_IN a_DT single_JJ methyl_NN group_NN )_) ,_,
        the_DT aptamer_NN became_VBD solely_RB responsive_JJ to_TO 3_CD -_: methylxanthine_NN 
        in_IN vivo_NN ._. Group_NNP I_PRP aptazymes_NNS may_MD have_VB
        a_DT number_NN of_IN important_JJ biotechnology_NN applications_NNS ,_, including_VBG
        use_NN as_IN 
        in_IN vivo_NN ,_, real-time_JJ reporters_NNS and_CC as_IN
        regulatable_JJ gene_NN therapeutics_NNS ._.
      
      
        Methods_NNP
        
          E_NNP ._. colistrains_NNS and_CC growth_NN media_NNS
          
          E_NNP ._. coli_NNS strain_VBP C_NNP 600_CD ThyA_NNP :_: :_: KanR_NNP was_VBD
          used_VBN for_IN the_DT plate_NN assays_NNS and_CC 
          in_IN vivo_NN growth_NN curves_NNS ._. INVaF_NNP '_POS
          (_( Invitrogen_NNP ,_, Carlsbad_NNP ,_, CA_NNP )_) was_VBD used_VBN for_IN cloning_VBG and_CC
          plasmid_NN amplification_NN ._. Bacterial_NNP starter_JJ cultures_NNS were_VBD
          grown_VBN in_IN LB_NNP supplemented_JJ with_IN thymine_NN (_( 50_CD mg_NN /_NN l_NN )_) ._.
          Screening_NNP for_IN thymidine_NN auxotrophy_NN was_VBD done_VBN in_IN minimal_JJ
          media_NNS supplemented_JJ with_IN 0_CD ._. 1_CD %_NN Norit_NNP A-_NNP treated_VBD casamino_NN
          acids_NNS (_( MM_NNP )_) and_CC MM_NNP supplemented_JJ with_IN thymine_NN (_( 50_CD mg_NN /_NN l_NN )_)
          (_( MMT_NNP )_) ._. Plates_NNP contained_VBD Bacto_NNP agar_NN (_( 1_CD ._. 5_LS %_NN )_) ._. Ampicillin_NNP (_( 50_CD
          mg_NN /_NN l_NN )_) and_CC kanamycin_NN (_( 100_CD mg_NN /_NN l_NN )_) were_VBD added_VBN to_TO all_DT growth_NN
          media_NNS ._.
        
        
          Construction_NNP of_IN the_DT tdintron_NN aptazymes_NNS
          The_DT wild_JJ type_NN plasmid_NN pTZtd_NN 1304_CD [_NN 17_CD ]_NN contains_VBZ a_DT
          fully_RB functional_JJ 265_CD nt_RB derivative_NN of_IN the_DT 1016_CD nt_RB wild_JJ
          type_NN intron_NN [_NN 15_CD ]_NN ._. This_DT derivative_NN also_RB contains_VBZ the_DT
          substitutions_NNS U_NNP 34_CD A_DT ,_, which_WDT introduces_VBZ a_DT SpeI_NNP site_NN ,_, and_CC
          U_NNP 976_CD G_NNP ,_, which_WDT introduces_VBZ an_DT EcoRI_NNP site_NN ._. The_DT constructs_NNS
          were_VBD made_VBN using_VBG standard_JJ solid_JJ phase_NN DNA_NNP synthesis_NN ,_, then_RB
          were_VBD PCR-amplified_NNP and_CC cloned_VBN into_IN pTZtd_NN 1304_CD ._. The_DT
          parental_JJ P_NN 6_CD aptazyme_NN construct_VB was_VBD generated_VBN by_IN two_CD
          overlapping_VBG oligos_NNS ,_, Gp_NNP 1_CD Wt_NNP 2_CD Gp_NNP 1_CD Wt_NNP 2_CD ._. 122_CD (_( GCC_NNP TGA_NNP GTA_NNP TAA_NNP
          GGT_NNP GAC_NNP TTA_NNP TAC_NNP TTG_NNP TAA_NNP TCT_NNP ATC_NNP TAA_NNP ACG_NNP GGG_NNP AAC_NNP CTC_NNP TCT_NNP
          AGT_NNP AGA_NNP CAA_NNP TCC_NNP CGT_NNP GCT_NNP AAA_NNP TTG_NNP TAG_NNP GAC_NNP TGC_NNP CCG_NNP GGT_NNP TCT_NNP
          ACA_NNP TAA_NNP ATG_NNP CCT_NNP AAC_NNP GAC_NNP TAT_NNP CCC_NNP TT_NNP )_) and_CC Gp_NNP 1_CD Wt_NNP 3_CD ._. 129_CD (_( TAA_NNP
          TCT_NNP TAC_NNP CCC_NNP GGA_NNP ATT_NNP ATA_NNP TCC_NNP AGC_NNP TGC_NNP ATG_NNP TCA_NNP CCA_NNP TGC_NNP AGA_NNP
          GCA_NNP GAC_NNP TAT_NNP ATC_NNP TCC_NNP AAC_NNP TTG_NNP TTA_NNP AAG_NNP CAA_NNP GTT_NNP GTC_NNP TAT_NNP CGT_NNP
          TTC_NNP GAG_NNP TCA_NNP CTT_NNP GAC_NNP CCT_NNP ACT_NNP CCC_NNP CAA_NNP AGG_NNP GAT_NNP AGT_NNP CGT_NNP TAG_NNP )_) ._.
          These_DT oligonucleotides_NNS (_( 100_CD pmole_NN )_) were_VBD annealed_JJ and_CC
          extended_VBN with_IN AMV_NNP reverse_VB transcriptase_NN (_( Amersham_NNP
          Pharmacia_NNP Biotech_NNP ,_, Piscataway_NNP ,_, NJ_NNP ;_: 45_CD units_NNS )_) in_IN AMV_NNP RT_NNP
          buffer_NN (_( 50_CD mM_NN Tris-_NNP HCl_NNP ,_, pH_NN 8_CD ._. 3_CD ,_, 8_CD mM_NN MgCl_NNP 
          2_CD ,_, 50_CD mM_NN NaCl_NNP ,_, 1_CD mM_NN DTT_NNP )_) and_CC dNTPS_NN
          (_( 200_CD Î¼M_NN )_) for_IN 30_CD minutes_NNS at_IN 37_CD Â°_NN C_NNP ._. The_DT resulting_VBG
          double-stranded_JJ DNA_NNP was_VBD diluted_VBN 1_CD :_: 50_CD and_CC amplified_VBN using_VBG
          primers_NNS SpeI_NNP ._. 24_CD (_( TTA_NNP TAC_NNP TAG_NNP TAA_NNP TCT_NNP ATC_NNP TAA_NNP ACG_NNP ;_: 0_CD ._. 4_CD Î¼M_NN )_)
          and_CC EcoRI_NNP ._. 24_CD (_( CCC_NNP GGA_NNP ATT_NNP CTA_NNP TCC_NNP AGC_NNP TGC_NNP ATG_NNP ;_: 0_CD ._. 4_CD Î¼M_NN )_) in_IN
          PCR_NNP buffer_NN (_( 10_CD mM_NN Tris-_NNP HCl_NNP ,_, pH_NN 8_CD ._. 3_CD ,_, 50_CD mM_NN KCl_NNP ,_, 1_CD ._. 5_CD mM_NN
          MgCl_NNP 
          2_CD ,_, 0_CD ._. 1_CD %_NN Triton_NNP X-_NNP 100_CD ,_, 0_CD ._. 005_CD %_NN
          gelatin_NN )_) ,_, dNTPS_NN (_( 200_CD Î¼M_NN )_) and_CC Taq_NNP DNA_NNP polymerase_NN (_( Promega_NNP ,_,
          Madison_NNP ,_, WI_NNP ;_: 1_CD ._. 5_CD units_NNS )_) ._. The_DT reactions_NNS were_VBD thermocycled_JJ
          15_CD times_NNS at_IN 94_CD Â°_NN C_NNP for_IN 30_CD seconds_NNS ,_, 45_CD Â°_NN C_NNP for_IN 30_CD seconds_NNS ,_,
          72_CD Â°_NN C_NNP for_IN 1_CD minute_NN and_CC then_RB purified_JJ with_IN a_DT QIAquick_NNP PCR_NNP
          purification_NN kit_NN (_( Qiagen_NNP ,_, Valencia_NNP ,_, CA_NNP )_) ._. The_DT PCR_NNP product_NN
          was_VBD digested_VBN with_IN SpeI_NNP (_( New_NNP England_NNP Biolabs_NNP ,_, Beverly_NNP ,_, MA_NNP ;_:
          20_CD units_NNS )_) and_CC EcoRI_NNP (_( 50_CD units_NNS )_) in_IN buffer_NN (_( 50_CD mM_NN NaCl_NNP ,_, 100_CD
          mM_NN Tris-_NNP HCl_NNP ,_, pH_NN 7_CD ._. 5_CD ,_, 10_CD mM_NN MgCl_NNP 
          2_CD ,_, 0_CD ._. 025_CD %_NN Triton_NNP X-_NNP 100_CD ,_, 100_CD Î¼g_NN /_NN ml_NN
          BSA_NNP )_) at_IN 37_CD Â°_NN C_NNP for_IN 60_CD minutes_NNS ,_, purified_JJ ,_, and_CC cloned_VBN into_IN
          SpeI_NNP /_NN EcoRI_NNP digested_VBN pTZtd_NN 1304_CD ._. The_DT negative_JJ control_NN and_CC
          aptazyme_NN constructs_NNS were_VBD made_VBN as_IN described_VBN except_IN that_DT
          Gp_NNP 1_CD Wt_NNP 3_CD ._. 129_CD was_VBD replaced_VBN with_IN oligonucleotides_NNS of_IN the_DT
          appropriate_JJ sequence_NN :_: B_NNP 11_CD GCC_NNP TGA_NNP GTA_NNP TAA_NNP GGT_NNP GAC_NNP TTA_NNP TAC_NNP
          TTG_NNP TAA_NNP TCT_NNP ATC_NNP TAA_NNP ACG_NNP GGG_NNP AAC_NNP CTC_NNP TCT_NNP AGT_NNP AGA_NNP CAA_NNP TCC_NNP
          CGT_NNP GCT_NNP AAA_NNP TGC_NNP CTA_NNP ACG_NNP ACT_NNP ATC_NNP CCT_NNP T_NN ,_, Th_NNP 1_CD P_NN 6_CD GCC_NNP TGA_NNP GTA_NNP
          TAA_NNP GGT_NNP GAC_NNP TTA_NNP TAC_NNP TTG_NNP TAA_NNP TCT_NNP ATC_NNP TAA_NNP ACG_NNP GGG_NNP AAC_NNP CTC_NNP
          TCT_NNP AGT_NNP AGA_NNP CAA_NNP TCC_NNP CGT_NNP GCT_NNP AAA_NNP TTA_NNP TAC_NNP CAG_NNP CAT_NNP CGT_NNP CTT_NNP
          GAT_NNP GCC_NNP CTT_NNP GGC_NNP AGA_NNP TAA_NNP ATG_NNP CCT_NNP AAC_NNP GAC_NNP TAT_NNP CCC_NNP TT_NNP ,_, Th_NNP 2_CD P_NN 6_CD
          GCC_NNP TGA_NNP GTA_NNP TAA_NNP GGT_NNP GAC_NNP TTA_NNP TAC_NNP TTG_NNP TAA_NNP TCT_NNP ATC_NNP TAA_NNP ACG_NNP
          GGG_NNP AAC_NNP CTC_NNP TCT_NNP AGT_NNP AGA_NNP CAA_NNP TCC_NNP CGT_NNP GCT_NNP AAA_NNP TTG_NNP ATA_NNP CCA_NNP
          GCA_NNP TCG_NNP TCT_NNP TGA_NNP TGC_NNP CCT_NNP TGG_NNP CAG_NNP CAT_NNP AAA_NNP TGC_NNP CTA_NNP ACG_NNP ACT_NNP
          ATC_NNP CCT_NNP T_NN ,_, Th_NNP 3_CD P_NN 6_CD GCC_NNP TGA_NNP GTA_NNP TAA_NNP GGT_NNP GAC_NNP TTA_NNP TAC_NNP TTG_NNP TAA_NNP
          TCT_NNP ATC_NNP TAA_NNP ACG_NNP GGG_NNP AAC_NNP CTC_NNP TCT_NNP AGT_NNP AGA_NNP CAA_NNP TCC_NNP CGT_NNP GCA_NNP
          TAC_NNP CAG_NNP CAT_NNP CGT_NNP CTT_NNP GAT_NNP GCC_NNP CTT_NNP GGC_NNP AGG_NNP CCT_NNP AAC_NNP GAC_NNP TAT_NNP
          CCC_NNP TT_NNP ,_, Th_NNP 4_CD P_NN 6_CD GCC_NNP TGA_NNP GTA_NNP TAA_NNP GGT_NNP GAC_NNP TTA_NNP TAC_NNP TTG_NNP TAA_NNP TCT_NNP
          ATC_NNP TAA_NNP ACG_NNP GGG_NNP AAC_NNP CTC_NNP TCT_NNP AGT_NNP AGA_NNP CAA_NNP TCC_NNP CGT_NNP GCT_NNP AAA_NNP
          TAT_NNP ACC_NNP AGC_NNP ATC_NNP GTC_NNP TTG_NNP ATG_NNP CCC_NNP TTG_NNP GCA_NNP GTA_NNP AAT_NNP GCC_NNP TAA_NNP
          CGA_NNP CTA_NNP TCC_NNP CTT_NNP ,_, Th_NNP 5_CD P_NN 6_CD GCC_NNP TGA_NNP GTA_NNP TAA_NNP GGT_NNP GAC_NNP TTA_NNP TAC_NNP
          TTG_NNP TAA_NNP TCT_NNP ATC_NNP TAA_NNP ACG_NNP GGG_NNP AAC_NNP CTC_NNP TCT_NNP AGT_NNP AGA_NNP CAA_NNP TCC_NNP
          CGT_NNP ATA_NNP CCA_NNP GCA_NNP TCG_NNP TCT_NNP TGA_NNP TGC_NNP CCT_NNP TGG_NNP CAG_NNP CTA_NNP ACG_NNP ACT_NNP
          ATC_NNP CCT_NNP T_NN ,_, Th_NNP 6_CD P_NN 6_CD GCC_NNP TGA_NNP GTA_NNP TAA_NNP GGT_NNP GAC_NNP TTA_NNP TAC_NNP TTG_NNP TAA_NNP
          TCT_NNP ATC_NNP TAA_NNP ACG_NNP GGG_NNP AAC_NNP CTC_NNP TCT_NNP AGT_NNP AGA_NNP CAA_NNP TCC_NNP CGT_NNP GAT_NNP
          ACC_NNP AGC_NNP ATC_NNP GTC_NNP TTG_NNP ATG_NNP CCC_NNP TTG_NNP GCA_NNP GCC_NNP TAA_NNP CGA_NNP CTA_NNP TCC_NNP
          CTT_NNP ,_, Th_NNP 1_CD P_NN 5_CD TGA_NNP GTA_NNP TAA_NNP GGT_NNP GAC_NNP TTA_NNP TAC_NNP TAG_NNP TAA_NNP TCT_NNP ATC_NNP
          TAA_NNP ACG_NNP GGG_NNP AAC_NNP CTC_NNP TAT_NNP ACC_NNP AGC_NNP ATC_NNP GTC_NNP TTG_NNP ATG_NNP CCC_NNP TTG_NNP
          GCA_NNP GAG_NNP ACA_NNP ATC_NNP CCG_NNP TGC_NNP TAA_NNP ATT_NNP GTA_NNP GGA_NNP CTG_NNP CCC_NNP GGG_NNP TTC_NNP
          TAC_NNP ATA_NNP AAT_NNP GCC_NNP TAA_NNP CGA_NNP CTA_NNP TCC_NNP CTT_NNP ,_, Th_NNP 2_CD P_NN 5_CD TGA_NNP GTA_NNP TAA_NNP
          GGT_NNP GAC_NNP TTA_NNP TAC_NNP TAG_NNP TAA_NNP TCT_NNP ATC_NNP TAA_NNP ACG_NNP GGG_NNP AAC_NNP CTA_NNP TAC_NNP
          CAG_NNP CAT_NNP CGT_NNP CTT_NNP GAT_NNP GCC_NNP CTT_NNP GGC_NNP AGA_NNP CAA_NNP TCC_NNP CGT_NNP GCT_NNP AAA_NNP
          TTG_NNP TAG_NNP GAC_NNP TGC_NNP CCG_NNP GGT_NNP TCT_NNP ACA_NNP TAA_NNP ATG_NNP CCT_NNP AAC_NNP GAC_NNP TAT_NNP
          CCC_NNP TT_NNP ,_, 3_CD Mex_NNP 2_CD P_NN 6_CD GTA_NNP ATC_NNP TAT_NNP CTA_NNP AAC_NNP GGG_NNP GAA_NNP CCT_NNP CTC_NNP TAG_NNP
          TAG_NNP ACA_NNP ATC_NNP CCG_NNP TGC_NNP TAA_NNP ATT_NNP GAT_NNP ACC_NNP AGC_NNP ATC_NNP GTC_NNP TTG_NNP ATG_NNP
          CCA_NNP TTG_NNP GCA_NNP GCA_NNP TAA_NNP ATG_NNP CCT_NNP AAC_NNP GAC_NNP TAT_NNP CCC_NNP TT_NNP ,_, and_CC
          Th_NNP 2_CD P_NN 6_CD ._. D_NNP GTA_NNP ATC_NNP TAT_NNP CTA_NNP AAC_NNP GGG_NNP GAA_NNP CCT_NNP CTC_NNP TAG_NNP TAG_NNP ACA_NNP
          ATC_NNP CCG_NNP TGC_NNP TAA_NNP ATT_NNP GAT_NNP ACC_NNP AGC_NNP ATC_NNP GTC_NNP TTG_NNP ATG_NNP CCC_NNP TTG_NNP
          GTT_NNP GCA_NNP TAA_NNP ATG_NNP CCT_NNP AAC_NNP GAC_NNP TAT_NNP CCC_NNP TT_NNP ._.
        
        
          In_IN vitrotranscription_NN
          The_DT introns_NNS were_VBD PCR-amplified_NNP with_IN KM_NNP 37_CD (_( GAT_NNP AAT_NNP ACG_NNP
          ACT_NNP CAC_NNP TAT_NNP AAT_NNP GGC_NNP ATT_NNP ACC_NNP GCC_NNP TTG_NNP T_NN )_) and_CC GM_NNP 24_CD (_( GCT_NNP CTA_NNP
          GAC_NNP TTA_NNP GCT_NNP ACA_NNP ATA_NNP TGA_NNP AC_NNP )_) in_IN 25_CD Î¼l_NN reactions_NNS under_IN the_DT
          conditions_NNS stated_VBN above_IN and_CC cycled_JJ 20_CD times_NNS ._. A_DT portion_NN of_IN
          the_DT reaction_NN (_( 5_CD Î¼l_NN )_) was_VBD run_VBN on_IN a_DT 3_CD %_NN agarose_NN gel_NN and_CC the_DT
          PCR_NNP product_NN band_NN was_VBD stabbed_VBN with_IN a_DT pipette_NN tip_NN ._. The_DT
          agarose_NN plug_NN was_VBD added_VBN to_TO a_DT fresh_JJ PCR_NNP reaction_NN (_( 100_CD Î¼l_NN )_)
          and_CC cycled_JJ 15_CD times_NNS ;_: DNA_NNP was_VBD purified_JJ using_VBG a_DT QIAquick_NNP
          kit_NN and_CC quantitated_JJ ._. The_DT PCR_NNP product_NN (_( 2_CD Î¼g_NN in_IN 50_CD Î¼l_NN )_) was_VBD
          added_VBN to_TO an_DT 
          in_IN vitro_NN transcription_NN reaction_NN
          containing_VBG Ampliscribe_NNP T_NN 7_CD RNA_NNP polymerase_NN (_( Epicentre_NNP )_) ,_,
          RNase_NNP inhibitor_NN (_( GIBCO_NNP BRL_NNP ,_, Rockville_NNP ,_, MD_NNP ;_: 5_CD units_NNS )_) ,_, low_JJ
          Mg_NNP 2_CD +_NN buffer_NN (_( 30_CD mM_NN Tris-_NNP HCl_NNP ,_, pH_NN 8_CD ,_, 7_CD ._. 5_CD mM_NN DTT_NNP ,_, 4_CD ._. 5_CD mM_NN
          MgCl_NNP 
          2_CD ,_, 1_CD ._. 5_CD mM_NN spermidine_NN )_) ,_, UTP_NNP (_( 1_CD ._. 25_CD mM_NN )_) ,_,
          ATP_NNP (_( 2_CD ._. 5_LS mM_NN )_) ,_, GTP_NNP (_( 2_CD ._. 5_LS mM_NN )_) ,_, CTP_NNP (_( 7_CD ._. 5_LS mM_NN )_) and_CC Î±-_NN 32_CD P_NN UTP_NNP
          (_( NEN_NNP ,_, Boston_NNP ,_, MA_NNP ;_: 20_CD Î¼Ci_NN ;_: 3000_CD mCi_NN /_NN mmol_NN )_) ,_, and_CC incubated_JJ
          at_IN 37_CD Â°_NN C_NNP for_IN 2_CD hours_NNS ._. DNase_NNP (_( GIBCO_NNP BRL_NNP ,_, 295_CD units_NNS )_) was_VBD
          added_VBN and_CC the_DT reaction_NN was_VBD incubated_JJ at_IN 37_CD Â°_NN C_NNP for_IN an_DT
          additional_JJ 30_CD minutes_NNS ._. The_DT RNA_NNP was_VBD purified_JJ using_VBG
          Centri-_NNP Sep_NNP columns_NNS (_( Princeton_NNP Separations_NNP ,_, Adelphia_NNP ,_, NJ_NNP )_)
          and_CC quantitated_JJ ._.
        
        
          In_IN vitrosplicing_VBG assays_NNS
          The_DT assays_NNS were_VBD performed_VBN by_IN heating_VBG the_DT RNA_NNP (_( 500_CD nM_NN )_)
          in_IN H_NNP 
          2_CD O_NNP to_TO 70_CD Â°_NN C_NNP for_IN 3_CD minutes_NNS then_RB
          transferring_VBG to_TO ice_NN for_IN 1_CD minute_NN ._. Splicing_NNP buffer_NN (_( 20_CD mM_NN
          Tris-_NNP HCl_NNP ,_, pH_NN 7_CD ._. 5_CD ,_, 100_CD mM_NN KCl_NNP ,_, 3_CD mM_NN MgCl_NNP 
          2_LS )_) ,_, effector_NN (_( theophylline_NN ,_, 1_CD ._. 5_CD mM_NN )_)
          was_VBD added_VBN and_CC the_DT reactions_NNS were_VBD incubated_JJ on_IN ice_NN for_IN an_DT
          additional_JJ 15_CD minutes_NNS ._. At_IN this_DT time_NN a_DT 4_CD ._. 5_CD Î¼l_NN aliquot_NN was_VBD
          removed_VBN for_IN a_DT zero_CD time_NN point_NN and_CC quenched_JJ with_IN 5_CD Î¼l_NN stop_NN
          dye_NN (_( 95_CD %_NN formamide_NN ,_, 20_CD mM_NN EDTA_NNP ,_, 0_CD ._. 5_CD %_NN xylene_NN cyanol_NN ,_, and_CC
          0_CD ._. 5_CD %_NN bromophenol_NN blue_JJ )_) ._. GTP_NNP (_( 50_CD Î¼M_NN )_) was_VBD added_VBN to_TO the_DT
          remaining_VBG reaction_NN (_( 5_CD Î¼l_NN total_JJ volume_NN )_) to_TO start_VB the_DT
          splicing_VBG reaction_NN ._. The_DT reaction_NN was_VBD incubated_JJ at_IN 37_CD Â°_NN C_NNP for_IN
          30_CD minutes_NNS and_CC then_RB terminated_VBD with_IN stop_NN dye_NN (_( 5_CD Î¼l_NN )_) ._. The_DT
          reactions_NNS were_VBD heated_VBN to_TO 70_CD Â°_NN C_NNP for_IN 3_CD minutes_NNS and_CC 5_CD Î¼l_NN was_VBD
          analyzed_VBN on_IN a_DT 8_CD %_NN denaturing_VBG polyacrylamide_NN gel_NN ._. The_DT gel_NN
          was_VBD dried_VBN ,_, exposed_VBN to_TO a_DT phosphor_NN screen_NN and_CC analyzed_VBD
          using_VBG a_DT Molecular_NNP Dynamics_NNP Phosphorimager_NNP (_( Sunnyvale_NNP ,_,
          CA_NNP )_) ._.
          The_DT reaction_NN volumes_NNS were_VBD increased_VBN for_IN the_DT rate_NN
          determination_NN assay_NN ._. Aliquots_NNP were_VBD taken_VBN at_IN intervals_NNS
          between_IN 0_CD minutes_NNS and_CC 15_CD minutes_NNS and_CC terminated_VBD with_IN stop_NN
          dye_NN ._. The_DT reactions_NNS were_VBD analyzed_VBN as_IN described_VBN above_IN ._. For_IN
          each_DT time_NN point_NN ,_, the_DT number_NN of_IN counts_NNS in_IN unreacted_JJ
          intron_NN ,_, spliced_JJ intron_NN ,_, and_CC circularized_JJ intron_NN were_VBD
          determined_VBN ._. Background_NNP counts_NNS were_VBD subtracted_VBN from_IN these_DT
          values_NNS ._. The_DT fraction_NN of_IN reacted_VBD intron_NN was_VBD then_RB
          calculated_VBN as_IN :_:
          
            
              (_( circular_JJ intron_NN +_NN spliced_JJ intron_NN )_)
              /_NN (_( unreacted_JJ intron_NN +_NN circular_JJ intron_NN +_NN spliced_JJ
              intron_NN )_) 
             
          
          The_DT individual_JJ time_NN points_NNS were_VBD averaged_VBN together_RB ,_, the_DT
          fraction_NN reacted_VBD was_VBD plotted_VBD versus_CC time_NN ,_, and_CC rate_NN
          constants_NNS were_VBD extracted_VBN by_IN fitting_JJ the_DT data_NNS to_TO a_DT
          single-exponential_JJ equation_NN :_:
          
            
            F_NN =_SYM 
            A_DT *_NN 
            e_SYM (_( -_: 
            kt_NN )_) 
          
          The_DT plotted_VBD data_NN and_CC rate_NN constants_NNS for_IN Th_NNP 1_CD P_NN 5_CD and_CC
          Th_NNP 2_CD P_NN 6_CD constructs_NNS are_VBP shown_VBN in_IN Figures_NNS 2_CD band_NN 2_CD cand_NN Table_NNP
          2_CD ._. The_DT changes_NNS in_IN the_DT extent_NN of_IN reaction_NN observed_VBD between_IN
          individual_JJ experiments_NNS ,_, and_CC thus_RB the_DT attendant_NN error_NN
          bars_NNS ,_, were_VBD consistent_JJ with_IN those_DT observed_VBN during_IN the_DT
          kinetic_JJ analyses_NNS of_IN other_JJ ribozymes_NNS ._. For_IN example_NN ,_, studies_NNS
          of_IN the_DT hairpin_NN ribozyme_NN have_VBP shown_VBN that_IN data_NNS points_NNS can_MD
          vary_VB between_IN individual_JJ experiments_NNS by_IN as_RB much_JJ as_IN 50_CD %_NN [_NN
          40_CD ]_NN ._. Our_PRP$ data_NNS points_NNS typically_RB varied_VBD from_IN one_CD another_DT
          by_IN less_JJR than_IN 30_CD %_NN ._.
        
        
          In_IN vivoplate_NN assay_NN
          The_DT plasmids_NNS containing_VBG the_DT various_JJ group_NN I_PRP constructs_NNS
          were_VBD transformed_VBN into_IN competent_JJ C_NNP 600_CD ThyA_NNP :_: :_: Kan_NNP Rcells_NNP and_CC
          grown_VBN in_IN LB_NNP with_IN kanamycin_NN overnight_JJ ._. A_DT small_JJ aliquot_NN (_( 3_CD
          Î¼l_NN )_) of_IN overnight_JJ cell_NN culture_NN was_VBD mixed_VBN with_IN effector_NN
          (_( theophylline_NN ,_, 7_CD ._. 5_CD mM_NN )_) or_CC H_NNP 
          2_CD O_NNP ,_, spotted_VBD on_IN plates_NNS ,_, and_CC grown_VBN
          overnight_JJ at_IN 37_CD Â°_NN C_NNP ._. As_IN a_DT positive_JJ control_NN ,_, all_DT constructs_NNS
          were_VBD also_RB plated_JJ on_IN minimal_JJ media_NNS plates_NNS with_IN thymine_NN
          (_( MMT_NNP )_) and_CC assayed_JJ for_IN viability_NN ._.
        
        
          In_IN vivogrowth_NN curves_NNS
          Cells_NNP grown_VBN overnight_JJ in_IN LB_NNP were_VBD diluted_VBN 1_CD :_: 100_CD in_IN MM_NNP
          containing_VBG either_CC theophylline_NN ,_, caffeine_NN ,_,
          3_CD -_: methylxanthine_NN or_CC no_DT effector_NN ,_, and_CC analyzed_VBD on_IN a_DT
          Microbiology_NNP Workstation_NNP Bioscreen_NNP C_NNP (_( Labsystems_NNP ,_, Inc_NNP ._. ,_,
          Franklin_NNP ,_, MA_NNP )_) ._.
        
        
          RT-PCR_NNP analysis_NN
          RNA_NNP was_VBD isolated_VBN from_IN an_DT overnight_JJ culture_NN using_VBG a_DT
          MasterPure_NNP RNA_NNP purification_NN kit_NN (_( Epicentre_NNP ,_, Madison_NNP ,_, WI_NNP )_)
          and_CC amplified_VBN by_IN RT-PCR_NNP using_VBG primers_NNS KM_NNP 37_CD and_CC GM_NNP 24_CD
          following_VBG the_DT protocol_NN provided_VBN for_IN Tth_NNP polymerase_NN ._. The_DT
          products_NNS were_VBD separated_JJ and_CC analyzed_VBD on_IN a_DT 3_CD %_NN agarose_NN
          gel_NN ._.
        
      
      
        Authors_NNP '_'' Contributions_NNP
        Kristin_NNP M_NNP ._. Thompson_NNP conceived_VBD of_IN ,_, designed_VBN ,_, and_CC carried_VBD
        out_IN most_JJS of_IN the_DT experiments_NNS described_VBD in_IN this_DT paper_NN and_CC
        analyzed_VBD the_DT resultant_JJ data_NN ._. Heather_NNP A_DT ._. Syrett_NNP repeated_VBD a_DT
        number_NN of_IN these_DT experiments_NNS and_CC showed_VBD that_IN the_DT 
        in_IN vivo_NN activation_NN of_IN the_DT intron_NN was_VBD
        reproducible_JJ ._. Scott_NNP M_NNP ._. Knudsen_NNP assisted_VBN in_IN data_NNS analysis_NN ._.
        Andrew_NNP D_NNP ._. Ellington_NNP conceived_VBD of_IN these_DT experiments_NNS and_CC
        assisted_VBN in_IN the_DT design_NN of_IN experiments_NNS and_CC data_NNS
        analysis_NN ._.
      
    
  
